Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis

Hetherington S, Texter M, Wenzel E, Patti JM, Reynolds L, Shamp T, Swan S. Antimicrob Agents Chemother. 2006;50(10):3499-3500.